BioCentury | Sep 1, 2018
Politics, Policy & Law

Back to School 2018: A pathway to Biopharma 3.0

...as well as new players such as Octave Bioscience Inc. UCB markets epilepsy drugs Briviact brivaracetam...
BioCentury | Apr 27, 2018
Company News

UCB buys rights to seizure candidate

...designations. UCB's existing epilepsy portfolio includes marketed drugs Briviact brivaracetam, Keppra levetiracetam and Vimpat lacosamide. Briviact...
BioCentury | Apr 20, 2018
Company News

UCB buys rights to seizure candidate

...designations. UCB's existing epilepsy portfolio includes marketed drugs Briviact brivaracetam, Keppra levetiracetam and Vimpat lacosamide. Briviact...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Nov 3, 2017
Regulation

Frame work

...of a treatment are worth its risks. The framework for UCB S.A.’s epilepsy drug Briviact brivaracetam...
...quantitative assessments of benefit and risk. Unger calculated that six patients would have to receive Briviact...
BioCentury | Feb 3, 2017
Clinical News

Briviact regulatory update

...FDA accepted for review an sNDA from UCB for Briviact brivaracetam as monotherapy to treat partial-onset...
...BioCentury, Feb. 29, 2016 ). UCB Group (Euronext:UCB), Brussels, Belgium Product: Briviact brivaracetam Business: Neurology Alex Himes brivaracetam Briviact UCB...
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are looking...
BioCentury | Jun 6, 2016
Company News

UCB sales and marketing update

...UCB launched Briviact brivaracetam in the U.S. to treat partial-onset seizures in epileptics ages 16 and...
...and Efficiency in Health Care (IQWiG) said in a dossier of early benefit assessment that Briviact...
BioCentury | Apr 4, 2016
Finance

1Q approvals

...asthma in adults with an eosinophilic phenotype UCB Group (Euronext:UCB) EC and FDA approve Briviact brivaracetam...
BioCentury | Mar 7, 2016
Company News

UCB sales and marketing update

...UCB launched Briviact brivaracetam in the U.K. as an adjunct therapy to treat partial-onset seizures in...
Items per page:
1 - 10 of 44